Travere Therapeutics/$TVTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Ticker

$TVTX
Primary listing

Industry

Biotechnology

Employees

385

ISIN

US89422G1076

TVTX Metrics

BasicAdvanced
$1.3B
-
-$2.78
0.88
-

What the Analysts think about TVTX

Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.

Bulls say / Bears say

FILSPARI® (sparsentan) achieved net product sales of $50 million in Q4 2024, contributing to total net product sales of $227 million for the year, indicating strong market adoption. (Travere Therapeutics Press Release)
The European Commission approved the conversion of FILSPARI's conditional marketing authorization to full approval for IgA Nephropathy, potentially expanding its market reach in Europe. (Business Wire)
Analysts maintain a 'Strong Buy' consensus with a 12-month price target of $33.31, suggesting a potential upside of approximately 64.66% from the current stock price. (Stock Analysis)
The Phase 3 HARMONY study of pegtibatinase was paused due to manufacturing scale-up issues, delaying enrollment resumption until 2026 and potentially impacting the drug's market entry timeline. (Investing.com)
Despite increased revenues, Travere reported a net loss of $321.55 million in 2024, a 188.6% increase from the previous year, raising concerns about profitability. (Stock Analysis)
Insider selling activity, including the sale of 40,000 shares by Director Gary A. Lyons, may signal potential concerns about the company's future performance. (American Banking and Market News)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

TVTX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TVTX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TVTX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs